Codex DNA, Inc. (DNAY) stock soared 11.10% in the pre-market trading session at the price of $10.41 following the licensing and collaboration agreement with Pfizer to develop EDS technology. Codex DNA focused on enabling quick, precise, and reproducible writing of DNA and mRNA for multiple downstream markets. The company is empowering scientists who invent synthetic biology solutions for global challenges.
DNAY Signed Collaboration Agreement with Pfizer
On 10th January 2022, DNAY reported a strategic partnership and licensing deal with Pfizer to further develop its EDS technology for mRNA-based vaccines and biopharmaceutical products. Codex DNA will also receive an upfront payment from Pfizer along with performance-based technical milestone payments.
Additionally, the company is qualified to acquire supplementary milestone payments based on the accomplishment of specified regulatory, development, and commercialization targets associated with products devised from Codex DNA’s technology and licensed under the contract. As per this deal, Pfizer acquires early access to state-of-the-art Codex DNA technology, including the use of SOLA (short oligo ligation assembly) EDS technology.
Chief executive officer of DNAY, Todd R. Nelson, commented that this collaboration and licensing agreement validates their enzymatic cutting-edge SOLA technology. It will accelerate research and development programs of vaccine and biotherapeutics to benefit humanity.
DNAY Released Synthetic Genome for Omicron Variant
Earlier on 23rd December 2021, DNAY published the release of a novel synthetic genome of covid-19 virus for the highly transmissible Omicron variant. World Health Organization (WHO) has identified Omicron as a Variant of Concern since it spreads rapidly than any other variant. The genome has built using the BioXp 3250 platform, an automated biology benchtop workstation for fast, precise, and reproducible writing of mRNA and DNA.
Todd R. Nelson remarked that they praised the outstanding work of South African scientists to characterize and identify the latest Covid-19 variant of concern. They want to celebrate their work by releasing this new genome catalog to enhance research access to labs globally. It reflects their continued dedication to providing resources and tools to scientists combating the pandemic.